Indication
Immune-related Adverse Events
3 clinical trials
3 products
2 drugs
Clinical trial
An Open-Label, Phase II Multicenter Study of Rituximab or Tocilizumab for Steroid-Dependent Immune-Related Adverse Events Due to Immune Checkpoint BlockadeStatus: Recruiting, Estimated PCD: 2024-05-01
Drug
TocilizumabDrug
VarlilumabClinical trial
A Single-cell Approach to Identify Biomarkers of Pulmonary Toxicity for Immune Checkpoint BlockadeStatus: Recruiting, Estimated PCD: 2024-01-31
Product
Immune checkpoint blockadeProduct
Targeted therapyClinical trial
Multicenter Retrospective Cohort Study on Patients Receiving Extracorporeal Photopheresis for Immune-related Adverse Events After Checkpoint Inhibitor TreatmentStatus: Completed, Estimated PCD: 2022-12-30
Product
ECP